Skip to main content
$152.50 $1.70 (1.1%)

09:57 AM EST on 02/22/24

BeiGene (NASDAQ:BGNE)

CAPS Rating: 3 out of 5

Current Price $152.50 Mkt Cap $14.4B
Open $152.93 P/E Ratio -16.28
Prev. Close $150.80 Div. (Yield) $0.00 (0.0%)
Daily Range $151.64 - $153.66 Volume 30,686
52-Wk Range $132.95 - $272.49 Avg. Daily Vol. 276,881

Caps

How do you think NASDAQ:BGNE will perform against the market?

Add Stock to CAPS Watchlist

All Players

39 Outperform
1 Underperform
 

All-Star Players

10 Outperform
1 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:BGNE Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TMFjimhalley (< 20)
Submitted June 21, 2021

It has a strong pipeline led by two main drugs as well as the ability to use its Chinese connections to help other pharmaceutical companies in collaboration efforts.

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:BGNE Summary

Fools bullish on NASDAQ:BGNE are also bullish on:

Fools bearish on NASDAQ:BGNE are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about BGNE.

Recs

1
Member Avatar TMFjimhalley (< 20) Submitted: 6/21/2021 7:42:58 PM : Outperform Start Price: $319.66 NASDAQ:BGNE Score: -72.80

It has a strong pipeline led by two main drugs as well as the ability to use its Chinese connections to help other pharmaceutical companies in collaboration efforts.

Recs

1
Member Avatar Bigsef77 (48.62) Submitted: 1/15/2019 3:16:53 PM : Outperform Start Price: $168.98 NASDAQ:BGNE Score: -87.32

BeiGene drug gets 'breakthrough therapy' designation from FDA
[MarketWatch]
Wallace Witkowski
,MarketWatch•January 14, 2019

U.S. shares of BeiGene Ltd. rose in the extended session Monday after the biotech drug developer said the Food and Drug Administration will expedite the regulatory process for one of its drugs. BeiGene ADRs rose 4% after hours, following a 4.6% decline to close at $137.55 Monday. The company said the FDA gave a "Breakthrough Therapy" designation to its mantle cell lymphoma treatment, meaning the experimental drug zanubrutinib will get expedited review and guidance from the agency.

Recs

0
Member Avatar freecapital (75.66) Submitted: 9/6/2018 6:52:27 AM : Outperform Start Price: $168.41 NASDAQ:BGNE Score: -85.08

innovator

Leaderboard

Find the members with the highest scoring picks in BGNE.

Score Leader

portefeuille

portefeuille (97.57) Score: +306.96

The Score Leader is the player with the highest score across all their picks in BGNE.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
portefeuille 97.57 2/10/2016 5/31/2021 Outperform NS $26.13 +477.11% +170.16% +306.96 0 Comment
jeepdrew222 46.00 9/8/2016 Outperform 5Y $29.68 +408.09% +130.96% +277.13 0 Comment
SeriousK 27.28 11/29/2016 Outperform 5Y $31.07 +385.36% +128.97% +256.39 0 Comment
portefeuille3 91.67 9/28/2016 Outperform 5Y $30.81 +389.45% +134.33% +255.12 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. efarev 30.92 5/23/2017 Outperform 5Y $36.87 +309.00% +110.42% +198.59 0 Comment
AtlanticoClub 85.23 7/24/2020 Underperform 5Y $223.20 -32.44% +57.41% +89.85 0 Comment
portefeuille2 97.70 9/1/2017 Outperform 5Y $69.45 +117.13% +103.66% +13.47 0 Comment
sublimeinvestor 27.40 8/8/2017 Outperform 5Y $77.30 +95.08% +103.32% -8.23 0 Comment
Plasmidologist 27.69 8/8/2017 Outperform 5Y $77.49 +94.61% +103.30% -8.69 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. SwampFox18 45.69 5/10/2022 Outperform 5Y $145.67 +3.52% +25.97% -22.46 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for BGNE.